Here we report on the induction of resistance to photodynamic therapy (PDT) in the ABCG2-high human breast cancer cell line MA11 after repetitive PDT, using either Pheophorbide A (PhA) or di-sulphonated meso-tetraphenylchlorin (TPCS 2a ) as photosensitizer. Resistance to PhA-PDT was associated with enhanced expression of the efflux pump ABCG2. TPCS 2a -PDT-resistance was neither found to correspond with lower TPCS 2a -accumulation nor reduced generation of reactive oxygen species (ROS). Crossresistance to chemotherapy (doxorubicin) or radiotherapy was not observed. TPCS 2a -PDT-resistant cells acquired a higher proliferation capacity and an enhanced expression of EGFR and ERK1/2. p38 MAPK was found to be a death-signalling pathway in the MA11 cells post TPCS 2a -PDT, contrasting the MA11/ TR cells in which PDT generated a sustained phosphorylation of p38 that had lost its death-mediated signalling, and an abrogated activation of its downstream effector MAPKAPK2. No difference in apoptosis, necrosis or autophagy responses was found between the treated cell lines. Development of TPCS 2a -PDT resistance in the MDA-MB-231 cell line was also established, however, p38 MAPK did not play a role in the PDT-resistance. MCF-7 cells did not develop TPCS 2a -PDT-resistance. Photochemical internalisation (PCI) of 1 pM of EGF-saporin induced equal strong cytotoxicity in both MA11 and MA11/TR cells. In conclusion, loss of p38 MAPK-inducing death signalling is the main mechanism of resistance to TPCS 2a -PDT in the MA11/TR cell line. This work provides mechanistic knowledge of intrinsic and acquired PDTresistance which is dependent on choice of photosensitizer, and suggests PCI as a rational therapeutic intervention for the elimination of PDT-resistant cells.
Introduction
Intrinsic or acquired resistance to cancer therapies, including photodynamic therapy (PDT), is a major cause of treatment failure and relapse [1] [2] [3] . Thus, identification of cellular resistance mechanisms and development of novel strategies that overcome resistance is imperative for the development of successful anti-cancer therapies.
PDT is approved worldwide as a treatment of several cancer types [4] . PDT is based on the preferential accumulation of a nontoxic, light sensitive compound (photosensitizer) in the tumour tissue, and a subsequent light excitation of the photosensitizer by an appropriate wavelength. This leads to energy transfer from the photosensitizer to molecular oxygen (O 2 ) or to other cellular components, resulting in generation of cytotoxic concentration of reactive oxygen species (ROS), of which singlet oxygen is the most abundant, resulting in peroxidation of vital cellular components and initiation of cell death mechanisms such as apoptosis, necrosis or autophagy [4] . PDT depends on the presence of oxygen, and lack of cytotoxic responses in hypoxic regions of the tumour is a major obstacle [4] . Moreover, intracellular antioxidants such as the glutathione system, superoxide dismutase, catalase and lipoamide de-hydrogenase may detoxify PDT-induced ROS, resulting in treatment resistance [4] [5] [6] . Prosurvival signalling have also been shown to be important cytoprotective factors causing PDT resistance [2, [7] [8] [9] [10] [11] . Of relevance for this study, several independent reports have also shown that repeated in vitro PDT-treatments with different photosensitizers result in acquired resistance [3, 12, 13] .
Photochemical internalization (PCI) is a minimally invasive intracellular drug delivery method under clinical evaluation [14] . PCI is based on endosomal or lysosomal membrane localization of the photosensitizer TPCS 2a (Fimaporfin) and co-treatment with drugs that are sequestered and degraded in the same vesicles. By light-controlled activation of the PCI-photosensitizer the membranes of these vesicles are ruptured, and the entrapped drugs are released into the cell cytosol (endosomal escape) where they can exert their effect [15] . PCI-induced circumvention of resistance to several clinically approved drugs (e.g. bleomycin and doxorubicin) and model drugs (e.g. ribosome-inactivating protein (RIP) toxins and immunotoxins) has been demonstrated [16] [17] [18] . We have in addition shown the feasibility of using PCI as an efficient strategy to kill cancer cells by immunotoxins targeting putative cancer stem cell (CSC) markers including CD133, CD44, CSPG4 and EpCAM [19] .
A variety of clinical photosensitizers are substrates of the efflux pump ABCG2 (BCRP) [20, 21] , which may have therapeutic implications due to the overexpression of ABCG2 in drug-resistant cancer stem cells (CSCs) [22] . PCI photosensitizers, including disulfonated meso-tetraphenylporphine (TPPS 2a ) and di-sulfonated aluminium phthalocyanine (AlPcS 2a ) are, however, not substrates of this marker [22] . In addition, we have also shown that TPPS 2a and TPCS 2a are not substrates of ABCB1/p-glycoprotein (Pgp)/ MDR1 [17, 18] . We recently reported that the ABCG2-overexpressing human breast cancer cell line MA11 is intrinsically resistant to Pheophorbide A (PhA)-PDT, in contrast to PDT with the non-ABCG2 substrate PCI photosensitizer TPCS 2a [22] . Altogether, these findings suggest that PCI-photosensitizers are candidates for PCI-mediated targeting of multi drug resistant (MDR) and CSCs.
We hypothesized that repeated cycles of PhA-PDT in MA11 will increase intrinsic PDT-resistance due to selection of cells overexpressing ABCG2, while repeated cycles of TPCS 2a -PDT will not cause acquired resistance. Since TPCS 2a is under clinical evaluation as a photosensitizer for PCI-enhanced drug delivery [14] , we also aimed to elucidate death or survival responses after TPCS 2a -PDT in breast cancer cells. In this study, we demonstrate that three cycles with PhA-PDT induce enhanced intrinsic PDT-resistance and, surprisingly, repeated cycles of TPCS 2a -PDT result in acquired PDT-resistance. While increased expression of ABCG2 was indicated as the mechanism for acquired PhA-PDT-resistance, increased proliferation capacity and loss of death signalling in the p38 MAPK pathway was indicated as the mechanisms for acquired TPCS 2a -PDT-resistance in the MA11 cells. Development of TPCS 2a -PDT resistance in the MDA-MB-231 cell line also resulted in dysregulation of p38 MAPK signalling; however this was not found to play a role for cytoprotection. On the other side MCF-7 cells did not develop resistance after repeated TPCS 2a -PDT. EGFR was found to be overexpressed in the TPCS 2a -PDT resistant MA11/TR cells. PCI of the EGFR-targeting toxin EGF-saporin was equally efficient in MA11 and MA11/TR cells, and this put forward PCI-based drug delivery as a rational intervention to overcome PDT-resistance.
Materials and methods

Cell lines and culturing
The MA11 human breast cancer cell line was originally obtained from Dr. Gunhild Maelandsmo, Department of Tumour Biology at Oslo University Hospital -Radiumhospitalet. Two PDT-resistant sub-cell lines (not clones) of MA11, MA11/PAR and MA11/TR, were generated by 3 repeated cycles of PhA-PDT and TPCS 2a -PDT, respectively. The triple negative human breast cancer cell line MDA-MB-231 (#HTB-26, ATCC, Manassas, VA, USA) and the oestrogen (+) and progesterone (+) and HER2 (À) human breast cancer cell line MCF7 (#HTB-22, ATCC). One resistant sub-line of MDA-MB-231, MDA-MB-231/TR, was generated after 3 repeated cycles of TPCS 2a -PDT. The cell lines were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% foetal calf serum (FCS) (PAA Laboratories GmbH, Pasching, Austria), 100 U/ ml penicillin (Sigma-Aldrich) ad 100 mg/ml streptomycin (SigmaAldrich) and grown and incubated at 37°C in a humidified atmosphere containing 5% CO 2 . re-exposed to PDT twice (totally 3 treatments in the course of 3 weeks).
Light source and photosensitizers
Illumination
PCI
In the PCI protocol, cells were co-incubated with 0.5 mg/mL TPCS 2a and 1 pM EGF-saporin for 18 h. Then cells were washed twice with PBS and incubated in drug-free medium for 4 h prior to light exposure as described in the PDT protocol. EGF-saporin was prepared as described by Weyergang et al. by combining biotinylated EGF and streptavidin-saporin by non-covalent binding in a 4:1 ratio [23] .
Cytotoxicity assays
Cells were seeded at a density of 5000 (MA11, MA11/TR and MA11/PAR), 1500 (MDA-MB-231 and MDA-MB-231/TR) and 1000 (MCF7 and MCF7/NTR) per well in 96 well plates (Nunc). Cell metabolic activity/viability was assayed by the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method [17] at 24, 48 or 72 h after light exposure as indicated. For the clonogenic cell survival assay [17] 1500 (MA11 and MA11/TR) and 300 (MDA-MB-231/-TR and MCF7/-NTR) cells were seeded in 6-well plates. The assay was performed 10-14 days post light exposure by methylene blue staining. Real-time monitoring of cell confluency (proliferation) was determined by the IncuCyte live cell imaging system 
Intracellular localization of TPCS 2a
Cells were seeded on 0.17 (±0.01)-mm-thick coverslips (Assistent, Glaswarenfabrik Karl Hecht, Sondheim, Germany) in fourwell plates and allowed to attach overnight. Then the cells were incubated with 0.5 mg/ml TPCS 2a for 18 h, and washed twice with PBS prior to 4 h incubation with drug-free medium. The coverslips were washed with cold PBS with Ca2+ and Mg2+ and carefully inverted onto a microscope slide (Menzel-Gläser, Gerhard Menzel, Braunschweig, Germany). Fluorescence microscopy was carried out with a Zeiss Axioplan epi-fluorescence and phase-contrast microscope using 63Â magnification with an oil immersion objective (Carl Zeiss AG, Oberkochen, Germany). The TPCS 2a fluorescence was recorded with an AxioCamMR3 camera (Carl Zeiss) using a 395-440 nm band pass excitation filter, a 460 nm dichroic mirror and a 620 nm long pass emission filter. Co-localization of TPCS 2a with LysoTracker Green (LTG) (Life Technologies, Carlsbad, CA, USA) was investigated by adding 0.33 mM LTG 30 min prior to microscopy (after PDT). For recording LTG fluorescence, a 470/40 nm band pass excitation filter, a 495 nm dichroic mirror and a 525/50 nm band pass emission filter were used.
Flow cytometry
Flow cytometry was performed by using an LSRII Flow Cytometer (Becton-Dickinson, San Jose, CA), and data were processed by the FlowJo version 7.6.5 software (Treestar, OR), as recommended by the Flow Cytometry Core Facility (Institute for Cancer Research, Oslo University Hospital). Cells were treated as indicated and filtered through a 5 ml round-bottom tube with a cell strainer cap (Becton-Dickinson) prior to flow cytometry.
Cellular accumulation of TPCS 2a
For quantification of TPCS 2a accumulation in the MA11 cell lines, 2 Â 10 5 cells were seeded in 6-well plates (Nunc), and incubated with 0.5 mg/ml TPCS 2a for 18 h. Then the cells were washed twice with PBS prior to 4 h incubation with drug-free medium. Subsequently, the cells were detached with trypsin, washed and analysed by flow cytometry. Live and single cells were gated based on forward (FSC) and side (SSC) scattering parameters. TPCS 2a was excited by a 100 mW 407 nm laser, and fluorescence was collected through a 660/20 nm emission filter combined with a 635 nm longpass dichroic filter.
Intracellular ROS detection
Two hundred thousand cells were seeded in 6 well plates and subjected to PDT as described above. Immediately after light exposure, the cells were incubated with 0.1 mM 2 0 ,7 0 -Dichlorofluorescin diacetate (DCFH-DA) (Sigma-Aldrich). After 1 h incubation, cells were detached with trypsin, washed once in PBS, and subsequently analysed by flow cytometry to detect the fluorescent DCF product which forms upon DCFH oxidation by ROS. DCF fluorescence was detected in live cells by excitation with a 50 mW 488 nm laser, and collected through a 525/50 nm or a 530/30 nm emission filter combined with a 505 nm longpass dichroic filter.
Ionizing radiation therapy
Cells were seeded in 6-well plates (Nunc) to obtain 100, 200, 400 and 800 colonies for doses of 0, 2, 4 and 6 Gy, respectively. Ionizing radiation was delivered by an X-ray generator (Faxitron CP160), Tucson, AZ, USA) (160 kV, 6.3 mA, dose rate 1 Gy/min). Relative colony-forming ability of the cells was measured 10 days after radiation. The plating efficiency (PE) and surviving fraction (SF) were calculated as shown in Eqs. (1) and (2) 
Immunodetection of proteins by Western blotting
Cells were lysed with 70 ml 1x Lane Marker Reducing Sample Buffer (Thermo Fischer Scientific, Waltham, MA, USA), or lysis buffer containing 62.5 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% glycerol, 50 mM dithiothreitol, 0.01% bromphenol blue, 1 mM NaF, and 20 mM b-glycerol phosphate, added 10 ml/ml protease inhibitor cocktail (Sigma-Aldrich), 10 ml/ml phosphatase inhibitor cocktail I (Sigma-Aldrich), 10 ml/ml phosphatase inhibitor cocktail II (Sigma-Aldrich), 1 mM phenylmethanesulfonyl fluoride and 1 mM Na 3 VO 4 . The samples were sonicated for 10-15 s and heated (95°C for 5 min). Then samples were subjected to gel electrophoresis on 4-20% precast gradient polyacrylamide gels (BioRad) and Western blotting by the Transblot Turbo system (BioRad, Hercules, CA, USA) as recommended by the producers. Protein expression and activation was detected by antibody stains of western blots as described in [18] , using primary antibodies for phospho-p38 (#9216), phospho-MAPKAPK-2 (Thr222) (#3316), LC3B (#2775), EGFR (#2232), STAT-3 (#8719), phospho-STAT-3 (#9131), ERK1/2 (#9120), phospho-ERK1/2 (#9106) and biotin (#7075) (Cell Signaling Technologies, Danvers, MA, USA), ABCG2 (Clone BXP-21) and GPx1 (sc-3206) (Sigma Aldrich), and secondary HRP conjugated antibodies for rabbit (#7074) and mouse (#7076) (Cell Signaling) in concentrations recommended by the producers. In addition to DNA measurements (DNA absorbance (260/230 nm)) for determination of gel application volume, control of loading was performed by Ponceau S. staining (Sigma). Quantification was performed by volume integrating measurements of the protein signals using the Image Lab 4.1 Software (Bio-Rad).
Immunocytochemistry
Exponentially growing MA11 and MA11/TR cells were transferred as cytospin on glass slides and fixed in acetone prior to immunocytochemical (ICC) detection of either EGFR or ABCG2. Primary antibody against EGFR (clone H11, #M3563, 1:200) was purchased from Dako, Glostrup, Denmark and primary antibody against ABCG2 (clone BXP-21, #B7059, 1:100) was purchased from Sigma-Aldrich. EnVision FLEX+, Mouse, High pH (#K8002, Dako) was used for the target retrieval and ICC staining.
Inhibition of the p38 MAPK pathway
To study the impact of p38 MAPK activation on the PDTinduced cytotoxic response, 0.02 mM of the p38 MAPK inhibitor SB203580 (Calbiochem, Merck, Darmstadt, Germany) was added to cells 1 h prior to and removed 1.5 h after PDT. Cell viability was assessed by the MTT method 48 h after light exposure.
ELISA assay
Apoptosis (addressed by p53, caspase-3, PARP and Bcl-2-associated death promotor (BAD) detection), and growth signalling (addressed by Akt1, ERK1/2 (p44/p42) and S6 detection) was analysed by using the PathScan Ò Apoptosis (#7105) and Growth (#7239) Multi-Target Sandwich ELISA Kits (Cell Signaling). Protein expression was detected according to the producer's protocol and related to the total protein concentration measured by the DC Protein Assay (Bio-Rad, Hercules, CA, USA). Cells were both harvested immediately after (for growth signalling analysis) and 20 h after (for apoptotic signalling analysis) PDT.
Apoptosis, necrosis and cell cycle analysis
The TUNEL, and propidium iodide/thiazole orange (PI/TO) based necrosis assay was used to study apoptotic and necrotic responses 20 h after PDT, respectively. The TUNEL assay relies on the identification of nicks present in fragmented DNA of apoptotic cells, identified by deoxynucleotidyl transferase (TdT). TdT catalyses the addition of labelled dUTPs which can be detected by flow cytometry [24] . Two hundred thousand cells were seeded per well in 6-well plates (Nunc) and treated with PDT (60 and 300 s light exposure). Twenty hours post treatment, cells in the medium and trypsinated cells were harvested together. Subsequently, cells were washed with PBS and resuspended in either 400 mL ice cold methanol (drop wise while vortexed) for TUNEL assay, or in PBS for necrosis assay. Methanol fixed cells were stored in À20°C for later analysis. Cells in PBS were immediately incubated with thiazole orange (TO) (diluted 1:250) on ice for 5 min, followed by propidium iodide (PI) (diluted 1:500) (both from the BD Cell Viability kit (Becton-Dickinson, San Jose, CA)) immediately before flow cytometry analysis. Single cells were gated based on SSC parameters, and fragments discriminated based on SSC and TO area. Necrotic cells were further gated based on SSC and PI area. TO and PI were excited by a 50 mW 488 nm and 40 mW 561 nm laser, respectively, and fluorescence collected through a 525/50 and 610/20 nm emission filter, combined with 505 and 600 nm longpass dichroic filter. Methanol fixed cells stored for TUNEL assay, were washed once with PBS, and added 35 mL TdT reaction mix (3.5 mL TdT Reaction Buffer, 2.1 mL 25 mM CoCl 2 , 0.35 mL Biotin-16-dUTP, 0.35 mL 10 mM DTT, 0.14 mL TdT enzyme, 28.58 mL ddH 2 -O) (Roche) and left for 30 min incubation at 37°C. Then the cells were washed twice with PBS and incubated with 50 mL streptavidin-Cy5 1:400 (GE Healthcare) in 5% milk in PBS for 30 min at room temperature. Then the cells were washed once with PBS and resuspended in 500 mL Hoechst 33258 (1.5 mg/mL) in PBS, and left overnight at 4°C before flow cytometry. The apoptotic fraction was gated based on Cy5 and Hoechst area. Cy5 and Hoechst 33258 were excited by a 40 mW 640 nm and 25 mW 405 nm or 100 mW 407 nm laser, respectively, and fluorescence collected through a 670/14 (Cy5) and 450/50 (Hoechst 33258) nm emission filter. REH cells (acute lymphocytic leukaemia) harvested 24 h after treatments with ionizing radiation (4 Gy) were used as positive control in the TUNEL experiments. Cell cycle analysis was performed on Hoechst 33258-stained cells from the TUNEL experiment, based on Hoechst area, and analysed by using the Dean-Jett-Fox model to define cell cycle distribution.
High-content microscopy for detection of LC3 puncta
Forty thousand MA11 or MA11/TR cells grown on coverslips were fixed in 10% neutral buffered formalin (Sigma-Aldrich) for at least 20 min. After washing thrice in PBS cells were treated with 50 mM NH 4 Cl in PBS for 10 min to quench free aldehyde groups, and washed another three times in PBS. Then cells were blocked and permeabilized for 1 h in PBS containing 1% BSA (SigmaAldrich) and 0.05% saponin, incubated with primary antibody rabbit anti-LC3 (MBL, PM036, detecting both LC3-I and LC3-II) for 1 h, washed thrice in PBS/BSA/saponin, incubated with secondary antibody Alexa488-donkey anti-rabbit (Jackson ImmunoResearch Laboratories, 711-545-152) for 1 h, washed three times in PBS and one time in water. The cells were then mounted in Mowiol containing 1 mg/ml Hoechst 33342 (Sigma-Aldrich). Images were obtained with an Olympus ScanR automated microscope system with an UPLSAPO 40x/0.95 objective. All images were taken with the same settings and the Olympus ScanR analysis software was used to count the number of cells, calculate the percentage of cells with LC3 puncta (granular fluorescence signal of autophagosomes) and the average number of LC3 puncta per cell.
Electron microscopy
One hundred and fifty thousand cells were seeded in 6 well plates and treated with TPCS 2a -PDT (60 s/0.81 J/cm 2 of light) as described above. At different time points post PDT the cells were fixed with 2% glutaraldehyde in 0.1 M cacodylate buffer and centrifuged after 10 min at room temperature at 10,000 rpm in a table top centrifuge. Postfixation was done in 1% Osmium (1 h) followed by 30 min 0.1% tannic acid, 1% Na 2 SO 4 for 5 min for neutralization, and en bloc staining for 30 min in 4% uranyl acetate. After dehydration in graded ethanol series, cells were embedded in Epon and polymerized for 48 h. Ultrathin sections were cut by Leica Ultracut, transferred onto formvar/carbon coated grids and observed at 80 kV in a Jeol JEM 1203 transmission electron microscope. Images were recorded with a Morada digital camera and iTEM software (Olympus, Muenster, Germany).
Statistical evaluations of data
To assess whether the means of the different treatment results were significantly different we used the two-sided Student's t test by Sigma Plot 12.5 if not otherwise stated. A significance level of p < 0.05 was considered as significant. When appropriate, significance was assessed by the two-way ANOVA with Bonferroni's correction as post-hoc tests.
Results
Acquired resistance to PDT is cell line dependent
MA11 cells challenged with !3 cycles of PhA-PDT (designated MA11/PAR) were found highly resistant to further treatment with PhA-PDT compared to the control naïve MA11 cells (Fig. 1A) . Efflux of PhA by the ABCG2 transporter has previously been reported as a mechanism of resistance to PhA-PDT [20, 22, 25] . Although the naïve MA11 cells have an intrinsically high expression of ABCG2, the ICC analysis of ABCG2 revealed an enhanced expression of the drug efflux pump in MA11/PAR cells as compared to the MA11 cells (Fig. 1B) . In addition, we observed a shift towards enhanced plasma membrane expression of ABCG2 in the MA11/ PAR side population cells (this is the population of cells with lowest Hoechst 33343 fluorescence due to ABCG2 efflux). A single treatment of MA11 cells with TPCS 2a -PDT resulted in a light dose-dose dependent decrease of cell viability 24 h post light exposure, while development of resistance to TPCS 2a -PDT (designated MA11/TR) was acquired after !3 treatment cycles of PDT (Fig. 1C) . The light dose needed to inactivate 50% of the MA11/TR cells viability (LD 50 ) was >3-fold higher compared to that of the naïve MA11 cells. In addition, the MA11 cells were found to be 3-fold more sensitive (p = 0.010) to TPCS 2a -PDT compared to the MA11/TR cells at a 120 s light dose. In addition, we observed a distinct shoulder of the viability curve of the MA11/TR cells (Fig. 1C) compared to the MA11 cells, which suggests activation of cytoprotective pathway(s) in the PDT-resistant cells. In fact, we observed a minor increase in MTT activity of the MA11/TR cell for the two lowest light doses. These results were validated by three independent clonogenic assays (data not shown).
Since TPCS 2a is a clinical relevant photosensitizer used in PCI, we decided to further elucidate the cellular mechanisms of the TPCS 2a -PDT-induced resistance in the MA11/TR cells. By quantifying the dynamics of changes in the cell confluency after TPCS 2a -PDT during a time course of 12.5 days, the IncuCyte live-cell imaging system revealed a much higher proliferation capacity of the MA11/TR cells compared to the MA11 cells (Fig. 1D) , based on phase contrast micrographs acquired up to 300 h after PDT (Fig. 1E) . The MA11/TR cells remained to be PDT-resistant after 20 passages (6 weeks and !50 cell cycles) post the last PDT exposure indicating development of acquired and persistent PDT resistance (data not shown).
By using the MTT-assay, a minor development of TPCS 2a -PDT resistance was observed in the MDA-MB-231 cell line (MDA-MB-231/TR) compared to naïve MDA-MB-231 cells (Fig. 1F) . However, the clonogenic assay revealed a 4-fold (p = 0.001) higher sensitivity of the MDA-MB-231 cells to TPCS 2a -PDT (at 2 min light exposure) as compared to the TPCS 2a -PDT-resistant MDA-MB-231/TR cells (Fig. 1G) . LD 90 of MDA-MB-231/TR was almost 2-fold increased compared to that of MDA-MB-231. On the contrary, no induction of TPCS 2a -PDT resistance in the MCF7/NTR cell line was observed by use of the MTT-assay (Fig. 1F) , and no significant differences were found by the clonogenic assay (Fig. 1H). 3.2. Equal uptake and localization of TPCS 2a and ROS generation after TPCS 2a -PDT PDT, including TPCS 2a -PDT, induces cell death due to excess generation of cytotoxic ROS concentrations [4, 18, 26] . Hence, we assessed if there were any differences in intracellular ROS formation post TPCS 2a -PDT between the MA11 and MA11/TR cell lines. For both cell lines, ROS-formation increased in a light dosedependent fashion, however, no difference in ROS-generation between the cell lines was observed 1 h post treatment ( Fig. 2A) . In line with this, the expression of the ROS scavenging protein glutathione peroxidase (GPx)1 was found similar in MA11 and MA11/ TR cells (data not shown).
TPCS 2a is neither a substrate of ABCG2 nor Pgp/MDR1 [22, 17] . Thus, we hypothesized that the resistance to TPCS 2a -PDT in the MA11/TR cells could partly be due to a reduced endocytosis or increased exocytosis rate of TPCS 2a . Flow cytometry was utilized to evaluate difference in intracellular accumulation of photoactive TPCS 2a in the MA11 and MA11/TR cell lines. However, no difference in relative TPCS 2a fluorescence between the cell lines was observed (Fig. 2B) at the time point relevant to perform light exposure (18 h +4 h chase in drug free medium).
Intracellular localization and fluorescence signals of TPCS 2a at the time corresponding to PDT were by epi-fluorescence microscopy found similar in both MA11 and MA11/TR (Fig. 2C) . In both cell lines, TPCS 2a -fluorescence puncta and co-localization with LTG was detected, indicating localization of TPCS 2a in endosomes and lysosomes. Upon TPCS 2a -PDT, diffuse LTG and TPCS 2a -fluorescence was observed, demonstrating cytosolic release and similar degree of photochemical destruction of endosomes and lysosomes.
Cell cycle distribution after TPCS 2a -PDT in MA11 and MA11/TR cells
We then addressed possible changes in cell cycle distribution between the cell lines after TPCS 2a -PDT. Twenty hours after treatment, it was found a light-dose dependent increase in G2/M phase accumulation in both MA11 and MA11/TR. However, no significant difference in the cell cycle distribution between the cell lines was observed (Fig. 3) .
Repeated TPCS 2a -PDT does not induce cross-resistance to chemoor radiotherapy
To evaluate potential development of therapy cross-resistance (chemo-or radiotherapy), MA11 and MA11/TR cells (that had been sub-cultured between 15-23 times) were treated with increasing concentrations of doxorubicin (Fig. 4A ) or ionizing radiation (Fig. 4B) . For both treatment options, the cytotoxic response data did not reveal any difference between the cell lines, indicating no cross-resistance to these therapies.
Apoptosis, necrosis and autophagy responses in MA11 and MA11/ TR cells following TPCS 2a -PDT
Development of PDT-resistance may be manifested by a dysregulation of the mode of death responses, e.g. the cancer cells gain cytoprotective pathway(s) that make them less prone to undergo apoptosis [2] . Hence, to assess a potential difference in cytocidal responses we evaluated the degree of apoptosis, necrosis and autophagy between MA11 and MA11/TR post TPCS 2a -PDT. TUNEL assay combined with PI/TO staining was used to identify the distribution of apoptosis and necrosis, respectively, in the fraction of all dead cells (normalized to 100%) 20 h after TPCS 2a -PDT (Fig. 5A) . Non-treated cells displayed a low apoptotic subfraction which was not significantly different between the cell lines. TPCS 2a -PDT increased the apoptotic subfraction significantly (P < 0.05) to about 40% in both cell lines. ELISA assay (Fig. 5B and C) was further used to detect key apoptotic proteins after TPCS 2a -PDT; no significant changes in apoptotic signalling involving p53, caspase-3 or poly ADP ribose polymerase (PARP) were revealed. However, the expression of the Bcl-2-associated death promoter (BAD) was found 2.8-fold higher (p = 0.022) in the untreated MA11 cells compared to the MA11/TR cells ( Fig. 5B and C) . However, upon PDT the MA11/ TR cells increased their expression of BAD by a factor of approximately 3 (p = 0.013), which is about at the same level of total BAD expression in the PDT-treated MA11 cells. No significant difference in p-BAD was observed between the cell lines.
To study the initiation of autophagy, the numbers of cells with LC3 puncta were counted. Within 20 h after TPCS 2a -PDT, approximately 55% (varying from 30 to 80% between the individual experiments) of the cells contained more than two LC3 puncta ( Fig. 6A ) with an average of about 8 puncta per cell (Fig. 6B) in both cell lines.
The fusion process of the autophagosomes with lysosomes further depends on the conversion of LC3-I to LC3-II. A strong conversion of LC3-I to LC3-II was observed on Western blot analysis in both MA11 and MA11/TR cells 20 h post TPCS 2a -PDT when compared to control cells, indicating the initiation of a fusion response (Fig. 6C) . No LC3 conversion could be observed at earlier time points after PDT. Electron microscopy ( Fig. 6D ) revealed typical dense multivesicular bodies (MVBs) in both MA11 and MA11/TR cells after one and two hours after PDT which were not found in controls. Four hours after TPCS 2a -PDT most of the vesicles displayed a dilated but still multivesicular morphology, as well as possibly fused MVBs. Twenty hours after TPCS 2a -PDT most endocytic structures regained dense MVB morphologies. A clear identification of autophagic structures was not possible. 
NT
p38MAPK-mediated death signalling is lost in the TPCS 2a -PDTresistant MA11/TR cells
We have previously demonstrated that p38 MAPK induces a death signal after PDT with di-sulphonated mesotetraphenylporphyrin (TPPS 2a ), a photosensitizer relevant for in vitro PCI [36] . Here we also reveal that TPCS 2a -PDT of both MA11 and MA11/TR cells strongly enhance the activation of p38 MAPK (phosphorylation on Thr180/Tyr182) immediately (5 min) after light exposure (Fig. 7A) . The phosphorylation of p38 MAPK was also found high at 2 h and relatively high at 20 h post PDT in the resistant MA11/TR cells, compared to the MA11 cells. Hence, TPCS 2a -PDT induced substantially prolonged p38 MAPK activation in the MA11/TR cells compared to the naïve MA11 cells.
Pre-treatment with the p38 MAPK inhibitor SB203580, revealed a significant increase in MA11 survival upon 60 s TPCS 2a -PDT (p < 0.05) (Fig. 7B) . The inhibitor was shown to abolish the phos- phorylation of the p38 downstream MAPK-activated protein kinase 2 (MK2) on Thr222, indicating decreased activity of p38 MAPK (Fig. 7C) . The Thr222 site is reported to be one of the essential phosphorylation sites for MK2's activity [27] . No significant effect on PDT-survival could be detected in MA11/TR cells treated with SB203580 (Fig. 7D ). In line with this, minor to no phosphorylation of MK2 could be found in the MA11/TR cells after TPCS 2a -PDT (Fig. 7C) . In contrast to the MA11 cells, no effect on cell survival by the p38 inhibitor SB203580 was observed in the PDT-treated MDA-MB-231 (Fig. 7E ) or MCF7 cells (Fig. 7F) , although a similar lack of MK-2 phosphorylation was observed in the MDA-MB-231/TR cells (Fig. 7G) .
Cytoprotective signalling in MA11 and MA11/TR cells after TPCS 2a -PDT
ELISA analysis of proteins associated with growth and proliferation was carried out 5 min after TPCS 2a -PDT to determine potential early PDT-induced changes in expression between the MA11 and MA11/TR cells ( Fig. 8A and B) . Neither phosphorylation of Akt1, ERK1/2 (p44/p42) nor S6 were found different between the cell lines at this time point.
The level of total ERK1/2 was also found lower in the nontreated MA11 cells (about half of what could be found in the non-treated MA11/TR cells at the 20 h harvest time point) (Fig. 8C) . The relative phosphorylation status of ERK1/2 normalized to total ERK1/2 expression and untreated cells, revealed an attenuation of ERK1/ 2a ctivity two hours after TPCS 2a -PDT in both cell lines (p < 0.001) (Fig. 8D) . The expression of total STAT-3 and its phosphorylation, which is regulated by Janus kinases in response to cytokines and growth factors, was not found significantly affected by TPCS 2a -PDT at any harvest time point, and did not differ between the cell lines (Fig. 8E) . The phosphorylation status and hence activation showed, however, a significant dephosphorylation 5 min after PDT in both cell lines (MA11, p = 0.015 and MA11/TR, p < 0.001) (Fig. 8F) . Twenty hrs after TPCS 2a -PDT of the MA11 cells, the phosphorylation level of STAT-3 had returned to that of control cells. In contrast, phosphorylation of STAT-3 in PDT-treated MA11/TR cells was near 2-fold increased (p = 0.009) compared to untreated MA11/TR control cells. MA11/TR cells compared to the MA11 cells was confirmed by ICC (Fig. 9B) . The overexpression of EGFR in the MA11/TR cells made us hypothesize that PCI-based EGFR-targeting could be a rational strategy to eliminate these PDT-resistant cells. Indeed, targeting of EGFR with TPCS 2a -based PCI of 1 pM EGF-saporin was sufficient to induce a strong cytotoxic response in both MA11 and MA11/TR cells compared to PDT or EGF-saporin alone (Fig. 9C) . For MA11/TR cells, PCI of EGF-saporin increased cell killing 2.8-fold over PDT alone at 150 s light exposure, compared to 1.9-fold increased cell killing in the MA11 cells at the same light dose.
Discussion
PDT can be curative in early stage tumours and some premalignant conditions. In contrast, for thick lesions or advanced cancers, recurrence of tumour after PDT is a clinical challenge [4] . The reason for recurrences after PDT is unclear, though limited light penetration in tumour tissue and cytoprotective mechanisms have been reported to play important roles [28] . Hence, repeated PDT has been suggested and shown to improve the clinical outcome in different cancers [29] [30] [31] and pre-malignant conditions [32, 33] . However, several independent laboratories have demonstrated development of in vitro PDT-resistance [2, 12, 13, 34] , and clinically, cytoprotective signalling including upregulation of phospho-ERK and EGFR in squamous cell carcinoma (SSC) after methyl-d-aminolevulinic acid (MAL)-PDT [3] . Investigation of cancer cell resistance mechanisms after PDT and repeated PDT is therefore important for the further development and improvement of PDT.
Hence, in this study we aimed to identify mechanisms behind PDT-resistance in human breast cancer cells that had been treated with several (n ! 3) rounds of PDT. We first selected the ABCG2-overexpressing cell line MA11 and treated the cells with PDT using two different photosensitizers, PhA or TPCS 2a , having completely different intracellular localization [22] and being either a substrate or a non-substrate of the drug efflux pump ABCG2, respectively. Previously we demonstrated that the MA11 cells are intrinsically resistant to PDT using the photosensitizer PhA [22] , which has been shown to be a substrate of the ABCG2 drug efflux pump [20, 22] . We recently demonstrated that it is possible to overcome the PhA-PDT resistance of the MA11 cells by blocking ABCG2 activity with Fumitremorgin C and the clinically relevant tyrosine kinase inhibitors imatinib and nilotinib [19] . Here we show that the degree of resistance is further enhanced when the MA11 cells are challenged by multiple rounds of PhA-PDT. We found that the PhA-PDT-resistant cells (MA11/PAR) expressed a higher plasma membrane level of ABCG2 than the naïve MA11 cells, demonstrating that repeated PhA-PDT of the MA11 cells results in a PDTmediated selection of ABCG2-high cells. TPCS2a is not an ABCG2 substrate [22] , rendering the MA11 cells sensitive to TPCS2a-PDT. Yet, here we show that the MA11 cells acquired PDT-resistance upon challenge with !3 rounds of TPCS2a-PDT. The TPCS 2a -PDT resistant cells were designated MA11/TR. Since TPCS2a is under clinical evaluation for the use as a photosensitizer in PCI, we wanted to focus only on this photosensitizer in details.
We have previously reported on cross-resistance to TPPS2a-and TPCS2a-PDT in the doxorubicin-resistant sarcoma cell line MES-SA/ Dx5 [17, 18] , which was correlated with ROS scavenging. Surprisingly, the TPCS 2a -PDT-resistant MA11/TR cells had no significant difference in ROS generation compared to the naïve MA11 cells post TPCS 2a -PDT. In addition, neither cross-resistance to doxorubicin nor ionizing radiation was established in the MA11/TR cells. In line with this one of the most important antioxidant enzymes in humans, the ROS scavenger GPx1 [18, 35] , was found equally expressed by MA11 and MA11/TR cells. Altogether, these findings strongly suggest that the development of TPCS 2a -PDT-resistance observed in the MA11/TR cells does not involve an enhanced capacity to scavenge ROS. A strong increase in phosphorylation (at Thr180 and Tyr182) of the stress responsive protein p38 MAPK immediately ($5 min) after TPCS 2a -PDT in both MA11 and MA11/TR was revealed, consistent with our recent reports using other cell lines [18, 36, 37] . One of the most striking observations in the present study is the highly increased activation of p38 MAPK after TPCS 2a -PDT in the MA11/ TR cell line. Furthermore, inhibition of p38 MAPK activation with SB203580 did not have any impact on survival of the MA11/TR cells after TPCS 2a -PDT. However, SB203580 strongly enhanced the viability of PDT-treated MA11 cells indicating that p38 MAPK activation induces death signalling in the PDT-sensitive naïve cells, in agreement with observations in other models [36] . Hence, the present report suggests that the PDT-resistant MA11/TR cells have lost their p38-mediated cell death signalling after TPCS2a-PDT, which is most likely the central resistance mechanism observed in these cells. No effect on survival of p38 inhibition was found in MDA-MB-231 cells, although the resistant MDA-MB-231/TR cells did not phosphorylate MK2 in response to TPCS 2a -PDT. The MCF7, which intrinsically shows low sensitivity to TPCS 2a -PDT was also not affected by SB203580. Our data therefore indicate that breast cancer cells with acquired resistance to TPCS 2a -PDT have a dysregulated p38 MAPK activity, which has lost (MA11/TR) or strongly reduced (MDA-MB-231) its ability to phosphorylate MK2. However, the implication of the activation of p38 MAPK for death signalling is cell line dependent. Together with p38 MAPK, MK2 is known to be involved in cellular processes including stress and inflammatory responses, cell proliferation and survival [38] . Activation of p38 may in addition cause mitotic arrest [39] which was indeed observed after TPCS 2a -PDT in the MA11 and MA11/TR cells, however, no difference in cell cycle distribution was observed. Of high relevance to our study is the work of the Gaestel lab, which demonstrated that MK2 knockout mice had enhanced stress resistance and survived bacterial LPS-induced endotoxin shock because of a 90% reduction in the expression of TNF-a [40] . In addition, Köpper et al. showed that inhibition or depletion of MK2 protected U2OS sarcoma cells from DNA damage-induced cell death after ultraviolet light or gemcitabine exposure [41] . Based on this and new data revealed in this study, we suggest that loss of MK2 activity protect breast cancer cells from ROS-induced cell death after PDT.
The enhanced proliferation of the MA11/TR cells compared to the MA11 cells, indeed, indicates a dysregulation of proliferation and/or survival signalling in this PDT-resistant cell line. This may be attributed to the strongly enhanced expression of total EGFR and ERK1/2 observed in untreated MA11/TR cells at relative low cell confluence. This is in agreement with a study of Gilaberte et al. which recently demonstrated that EGFR is upregulated in relapsed SSC tumours of patients treated with MAL-PDT and in a SSC-13 sub-line that had developed PDT-resistance after multiple treatments with MAL-PDT [3] . Of relevance, some observational clinical case reports have shown that multiple PDT sessions may transform the tumour into a faster growing condition [42] [43] [44] . In contrast, PDT-mediated inhibition of total and phosphorylated EGFR expression immediately after treatment has been reported by us and others [45] [46] [47] using different cell line models and photosensitizers. Moreover, immunoblotting after TPCS 2a -PDT revealed that the EGFR downstream proteins ERK1/2, which are protein-serine/threonine kinases that participate in the Ras-Raf-MEK-ERK signal transduction cascade, were dephosphorylated in the MA11 and MA11/TR cells 2 h after treatment. The amount of phosphorylated total ERK1/2 was, however, higher in the MA11/ TR cells, coinciding with a higher proliferation rate in the MA11/ TR cells. Of relevance, p38 MAPK-induced G2/M arrest has been linked to de-phosphorylation of ERK1/2 [48] . The MA11 and MA11/TR cell lines responded, however, similar to TPCS 2a -PDT with respect to cell cycle distribution 20 h after TPCS2a-PDT; both gained a distinct accumulation in G2/M phase, which has also been reported previously by others using different photosensitizers e.g. Hypericin, AlPCS4 and TPPS4 where the latter two localize to endosomes and lysosomes [49] [50] [51] . Thus, increased EGFR and Erk expression may play an important role for the increased proliferation rate observed for the TPCS 2a -PDT resistant MA11/TR cells, and, in addition to the deregulated p38 MAPK signalling pathway, may partly explain the enhanced survival after PDT.
The rupture of endosomal and lysosomal membranes after light activation of PCI-photosensitizers as shown in Fig. 2D , is utilized to enhance the cytosolic delivery of several types of macromolecular drugs (e.g. protein-based toxins and targeting toxins) and some chemotherapeutics for cancer therapy [22, 26, [52] [53] [54] . Regardless of PDT sensitivity, which may vary with accumulation, localization and/or death and survival signalling of treated cancer cells, we have demonstrated that PCI of ribosomal inactivating toxins (e.g. saporin and gelonin), of which only 1-10 molecules may be sufficient to kill a cell [55] , with or without targeting moieties (e.g. growth factors and antibodies), circumvent therapy resistance in a number of cancer types [16] [17] [18] . Due to the elevated EGFR expression in the MA11/TR cells, we hypothesized that these cells would be sensitive to PCI of an EGFR-targeting drug. Indeed, PCI of 1 picomolar EGF-saporin decreased viability more in MA11/TR than in MA11 cells when compared to their PDT-sensitivities, demonstrating that PCI of EGF-saporin overcomes the PDTresistance in the MA11/TR cells. This is consistent with what we have previously observed in other cancer cell lines exhibiting different PDT sensitivities [18] .
A TPCS 2a -PDT-induced de-phosphorylation of STAT-3 was also detected by immunoblotting in both MA11 and MA11/TR cells at the Tyr705 site. These observations are in line with Liu et al., which reported on reduced STAT-3 and ERK1/2 phosphorylation upon 5-aminolevulinic acid (5-ALA)-PDT [46] . Twenty hours after TPCS 2a -PDT, the MA11/TR cells regained phosphorylation of STAT-3 exceeding the phosphorylation of untreated cells, also in line with their higher proliferation capacity compared to the naïve MA11 cells after PDT.
Twenty hrs after TPCS 2a -PDT the total distribution of cells undergoing apoptosis and necrosis was not different between the MA11 and MA11/TR cells. Moreover, ELISA performed immediately after PDT did not reveal any significant changes and differences of cell death or survival signalling responses, except a significant (p = 0.022) 3-fold lower expression of the BAD protein, which is a pro-apoptotic member of the Bcl-2 gene family, in the MA11/TR cells as compared to MA11 cells. However, in the resistant cells, TPCS 2a -PDT generated a significant 3-fold increase (p = 0.013) of BAD to the same level as the treated MA11 cells.
The pro-apoptotic activity of BAD is prevented by phosphorylation of Ser112 by the MAPK pathway [56] and Ser136 by the PI3K-Akt pathway [57] . No significant change in phospho-BAD level was, however, observed. Altogether, this proposes apoptotic signalling to not be part of the resistance mechanism, although the reduced expression of Bad in the non-treated MA11/TR cells may influence the enhanced viability of these cells.
TPCS 2a -PDT in MA11 and MA11/TR cells induced an increase in LC3 puncta and LC3-I to II conversion and this may indicate an autophagy induction. Despite an enlargement of multivesicular bodies (MVBs) and possibly an increase in MVB fusion profiles at 1-4 h post PDT, there was no clear evidence for an increased number of autophagosomes. However, the accumulation of LC3-II in MA11 and MA11/TR could indicate that the constitutive LC3-II turnover in the endo-/lysosomal pathway is reduced, possibly due to photochemical-induced damage to the membranes of the lysosomes, which was indeed revealed by the LTG micrographs post PDT. Interestingly, the ruptures of lysosomal membranes could indicate that LC3-II containing autophagic membranes are not degraded due to failure to be incorporated in the autolysosomal degradation pathway. However, we cannot rule out the possibility of increased autophagic activity due to the PDT-treatment, but this needs to be studied in more detail.
In summary, here we demonstrate that development and mechanisms of PDT-resistance after repeated cycles of PDT is both dependent on cell line and type of photosensitizer. The p38 MAPK signalling pathway is highly dysregulated in TPCS 2a -PDT-resistant cells, of which the MA11/TR cells have lost the p38-mediated cell death response after PDT, while PDT-induced death in MDA-MB-231/TR cells is independent of the p38 signalling. MA11/TR cells had a higher basal expression of EGFR and ERK1/2, and a stronger activation of P-STAT-3 upon TPCS2a-PDT, which may explain their enhanced proliferation capacity as compared to the naïve MA11 cells. Acquired TPCS2a-PDT-resistance did not result in development of cross-resistance to chemo-or radiotherapy, and no difference in mode of death distribution (necrosis, apoptosis or autophagy) after TPCS 2a -PDT. Finally, TPCS 2a -PCI-based targeting of EGFR overcome PDT-resistance and PCI will therefore be further evaluated for the treatment of therapy-resistant, aggressive and inoperable cancers.
